Skip to content

Study · Non-randomized trial · n = 50 · 1998

6 results

Changes in body composition in women treated with gonadotropin-releasing hormone agonists.

Revilla R, Revilla M, Villa LF, Cortés J, Arribas I, Rico H

Maturitas1 Nov 1998Cited by 20 (Europe PMC)

PMID10091206 (opens in a new tab)DOI10.1016/s0378-5122(98)00080-2 (opens in a new tab)PepBankPUB-10091206
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In eugonadal women, triptorelin increased fat content from baseline.

    In plain wordsIn women, triptorelin increased body fat from baseline.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseFat content
    Study

    n = 50

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    3.75 mg every 28 days · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Fat content change
    9.5%
    from baseline

    Source sentences

    Summary
    There were significant increases in fat content (9.5%, P < 0.0005) and weight (1.3%, P < 0.01), and significant decreases in fat-free mass (-1.9%, P < 0.0001) and water content (-1.8%, P < 0.0002).
    1 context sentence
    Summary · context
    We studied these changes using dual-energy X-ray absorptiometry in 50 eugonadal women treated with decapeptyl (Triptoreline), 3.75 mg injected intramuscularly, at 28-day intervals for 6 months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In eugonadal women, triptorelin increased weight from baseline.

    In plain wordsIn women, triptorelin increased weight from baseline.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    IncreaseBody weight
    Study

    n = 50

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    3.75 mg every 28 days · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Weight change
    1.3%
    from baseline

    Source sentences

    Summary
    There were significant increases in fat content (9.5%, P < 0.0005) and weight (1.3%, P < 0.01), and significant decreases in fat-free mass (-1.9%, P < 0.0001) and water content (-1.8%, P < 0.0002).
    1 context sentence
    Summary · context
    We studied these changes using dual-energy X-ray absorptiometry in 50 eugonadal women treated with decapeptyl (Triptoreline), 3.75 mg injected intramuscularly, at 28-day intervals for 6 months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In eugonadal women, triptorelin decreased fat-free mass from baseline.

    In plain wordsIn women, triptorelin decreased fat-free mass from baseline.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseFat-free mass
    Study

    n = 50

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    3.75 mg every 28 days · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Fat-free mass change
    −1.9%
    from baseline

    Source sentences

    Summary
    There were significant increases in fat content (9.5%, P < 0.0005) and weight (1.3%, P < 0.01), and significant decreases in fat-free mass (-1.9%, P < 0.0001) and water content (-1.8%, P < 0.0002).
    1 context sentence
    Summary · context
    We studied these changes using dual-energy X-ray absorptiometry in 50 eugonadal women treated with decapeptyl (Triptoreline), 3.75 mg injected intramuscularly, at 28-day intervals for 6 months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In eugonadal women, triptorelin decreased water content from baseline.

    In plain wordsIn women, triptorelin decreased body water from baseline.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseWater content
    Study

    n = 50

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    3.75 mg every 28 days · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Water content change
    −1.8%
    from baseline

    Source sentences

    Summary
    There were significant increases in fat content (9.5%, P < 0.0005) and weight (1.3%, P < 0.01), and significant decreases in fat-free mass (-1.9%, P < 0.0001) and water content (-1.8%, P < 0.0002).
    1 context sentence
    Summary · context
    We studied these changes using dual-energy X-ray absorptiometry in 50 eugonadal women treated with decapeptyl (Triptoreline), 3.75 mg injected intramuscularly, at 28-day intervals for 6 months.
  5. 05HumanNon-randomized trialSafety outcome

    In eugonadal women, triptorelin reduced axial bone mass from baseline.

    In plain wordsIn women, triptorelin reduced bone mass in the axial skeleton from baseline.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    DecreaseAxial bone mass
    Study

    n = 50

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg every 28 days · intramuscular · 6 monthsAs given in this study (human).

    Measurements

    Axial bone mass change
    −3.6%
    from baseline

    Source sentences

    Summary
    Bone mass was lost in the axial skeleton (-3.6%, P < 0.0001) but not in the peripheral skeleton.
    1 context sentence
    Summary · context
    We studied these changes using dual-energy X-ray absorptiometry in 50 eugonadal women treated with decapeptyl (Triptoreline), 3.75 mg injected intramuscularly, at 28-day intervals for 6 months.
  6. 06HumanNon-randomized trialSafety outcome

    In eugonadal women, peripheral bone mass was not lost during triptorelin treatment.

    In plain wordsIn women, peripheral bone mass did not decrease during triptorelin treatment.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    No significant changePeripheral bone mass
    Study

    n = 50

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    3.75 mg every 28 days · intramuscular · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    Bone mass was lost in the axial skeleton (-3.6%, P < 0.0001) but not in the peripheral skeleton.
    1 context sentence
    Summary · context
    We studied these changes using dual-energy X-ray absorptiometry in 50 eugonadal women treated with decapeptyl (Triptoreline), 3.75 mg injected intramuscularly, at 28-day intervals for 6 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.